Kolon TissueGene Q1 2026: Phase 3 Trial on Track, Net Loss Swells Due to Large Derivative Valuation Loss

TG-C (osteoarthritis cell gene therapy) US Phase 3 trial completed patient dosing (July 2024), follow-up ongoing; preparing BLA submission to FDA
Q1 2026 standalone net loss USD 68.2M (vs USD 4.0M in Q1 2025), primarily due to USD 64.7M derivative valuation loss
Operating loss USD 3.7M (vs USD 3.7M), revenue USD 0.96M (distribution business). No bio segment revenue
Total assets USD 337M, total liabilities USD 255M, equity USD 82.5M. Debt-to-equity ratio 233%
Cash and cash equivalents (including ST financial instruments) USD 80.7M (Dec 2025: USD 57.2M). Managing cash burn rate
Both pivotal studies of Phase 3 (1,020 patients) fully enrolled; patients in 2-year post-dose follow-up
Capital raised via third-party allotment (~KRW 60B) and conversion of convertible bonds. Outstanding CB USD 39.4M, embedded derivative liability USD 192M
Capitalized development costs (intangibles) USD 235M. Auditor identified development cost recognition and impairment as key audit matter
Multiple lawsuits in Korea (shareholder/patient damage claims ~KRW 56B). Criminal case concluded with acquittal
No dividends. Basic EPS -USD 4.09 (vs -USD 0.25). No shareholder return plan due to persistent losses